Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2020, with a specific transaction date of April 29, 2020. The document serves as a transaction notification regarding share allocations for Non-Executive Directors under the company's share allocation arrangements for the service period of January 1, 2020, to March 31, 2020.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific equity transactions involving Persons Discharging Managerial Responsibilities (PDMRs).
| Director Name | Position | Instrument | Volume | Price |
|---|---|---|---|---|
| Sir Jonathan Symonds | Non-Executive Chairman | Ordinary Shares | 2,584.170 | £16.93 |
| Mr Vindi Banga | Senior Independent Non-Executive Director | Ordinary Shares | 646.043 | £16.93 |
| Dr Vivienne Cox | Independent Non-Executive Director | Ordinary Shares | 461.459 | £16.93 |
| Ms Lynn Elsenhans | Independent Non-Executive Director | ADSs | 717.329 | $42.41 |
| Dr Laurie Glimcher | Independent Non-Executive Director | ADSs | 1,176.571 | $42.41 |
| Dr Jesse Goodman | Independent Non-Executive Director | ADSs | 370.051 | $42.41 |
| Ms Judy Lewent | Independent Non-Executive Director | ADSs | 389.027 | $42.41 |
| Mr Urs Rohner | Independent Non-Executive Director | Ordinary Shares | 609.126 | £16.93 |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents the routine acquisition of notional shares and ADSs by Non-Executive Directors as compensation for the first quarter of 2020.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory disclosure of director share transactions.
Investor Verification Points
- Verify that the share allocations align with the company's approved remuneration policy for Non-Executive Directors.
- Confirm the exchange rate used to value the Ordinary Shares (£16.93) versus the ADSs ($42.41) at the time of the transaction on April 29, 2020.
- Ensure the total volume of shares allocated matches the aggregate compensation entitlement for the Q1 2020 service period.